Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for non-infectious anterior uveitis has been reported in the published literature.
No approved treatments are currently available for non-infectious anterior uveitis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for non-infectious anterior uveitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for non-infectious anterior uveitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE3, 1 PHASE2. Research is primarily industry-sponsored.
13 publications have been identified in PubMed for non-infectious anterior uveitis. Research spans Epidemiology / Natural History (46%), Clinical Trial Publication (31%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 6 | 46% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Humira | adalimumab | AbbVie, Inc. | 2014 | 2023 | Designated (drug approved for other indication) |
Gene therapy approaches for non-infectious anterior uveitis have been reported in the published literature.
2 trials found
Clinical study results | 4 | 31% |
Testing and diagnosis research | 1 | 8% |
Patient case studies | 1 | 8% |
New treatment approaches | 1 | 8% |
Mrazovac Zimak D (2026). [PMID: 42074668](https://pubmed.ncbi.nlm.nih.gov/42074668/). *J Clin Med*. [Diagnostic / Biomarker]
Ding G (2026). [PMID: 41817860](https://pubmed.ncbi.nlm.nih.gov/41817860/). *International ophthalmology*. [Clinical Trial Publication]
Wu S (2026). [PMID: 42015780](https://pubmed.ncbi.nlm.nih.gov/42015780/). *J Tradit Chin Med*. [Clinical Trial Publication]
Oyeniran E (2026). [PMID: 41817272](https://pubmed.ncbi.nlm.nih.gov/41817272/). *Ocular immunology and inflammation*. [Epidemiology / Natural History]
Zhang H (2025). [PMID: 38749068](https://pubmed.ncbi.nlm.nih.gov/38749068/). *Ocular immunology and inflammation*. [Epidemiology / Natural History]
Siiskonen M (2025). [PMID: 40327203](https://pubmed.ncbi.nlm.nih.gov/40327203/). *Journal of ophthalmic inflammation and infection*. [Epidemiology / Natural History]
Barman Kakil Ş (2025). [PMID: 40638894](https://pubmed.ncbi.nlm.nih.gov/40638894/). *Ocular immunology and inflammation*. [Case Report / Case Series]
Sharon Y (2025). [PMID: 39931957](https://pubmed.ncbi.nlm.nih.gov/39931957/). *Ocular immunology and inflammation*. [Epidemiology / Natural History]
Olivas-Vergara OM (2025). [PMID: 40084348](https://pubmed.ncbi.nlm.nih.gov/40084348/). *Frontiers in ophthalmology*. [Gene Therapy / Novel Therapeutics]
Unknown (2025). [PMID: 38438812](https://pubmed.ncbi.nlm.nih.gov/38438812/). *Die Ophthalmologie*. [Clinical Trial Publication]